Korro Bio Inc (KRRO)
Korro Bio, Inc. is a NASDAQ-listed common stock company in the biotechnology sector focused on genetic medicines built on RNA editing. The biopharmaceutical company is working to discover, develop, and commercialize treatments for rare and more widely prevalent diseases in the United States. Its lead candidate is KRRO-121, which is being developed for hyperammonemia. Korro Bio’s platform, Oligonucleotide Promoted Editing of RNA, is designed to generate differentiated RNA editing product candidates, and the pipeline also includes programs in Parkinson’s disease, amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. The company also has a collaboration agreement with Novo Nordisk A/S aimed at cardiometabolic diseases. Founded in 2018, Korro Bio is based in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KRRO
|
$15.35
|
28.9% Upside
|
Undervalued
|
$20
|
67.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-1.5x
|
1.4x
|
44.9x
|
165.9 M
|
58.326 M
|
20.5%
|
66.1%
|
-2.3
|
—
|
62.2%
|
